Conferences

November 2023; Boston, Massachusetts Oral Presentation: The Exploring the Development of RRx-001: the NLRP3 Small Molecule Inhibitor for a Variety of Inflammatory Diseases

November 2023; Washington D.C. Oral Presentation: The CNS-permeable NLRP3 inhibitor RRx-001 is neuroprotective in experimental models of Parkinson’s disease

March 2023, Gothenburg Sweden Oral Presentation: RRx-001, A Direct NLRP3 Inhibitor and Phase 3 Small Molecule Improves Alzheimer’s and Parkinson’s Pathology in Multiple Disease Models

February 2023, San Francisco, California Poster: Effect of RRx-001 on nephrotoxicity of cisplatin/etoposide in patients with solid tumors

January 2023, San Francisco, California Poster: Phase 2 randomized, active-controlled, multicenter trial to assess the safety and efficacy of RRx-001 + irinotecan vs. regorafenib + irinotecan in third/fourth-line colorectal cancer.

November 2022, Boston, Massachusetts Oral Presentation: RRx-001, a Small Molecule Anticancer Agent in Phase 3, Protects Against Inflammasome-Driven Diseases Evaluate strategy and execution of drug design and translational development Understanding relevant pathology...

November 2022, San Diego, California Oral Presentation: The NLRP3 inhibitor RRx-001 crosses the blood brain barrier and alleviates neuroinflammation in experimental models of Parkinson’s disease

July 2022, San Diego, California Poster: The direct NLRP3 inhibitor and Phase 3 anticancer agent, RRx-001, ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice

June 2022, San Francisco, California Poster: The NLRP3 inhibitor and Nrf2 agonist, RRx-001, ameliorates non-alcoholic fatty liver disease (NAFLD/NASH) in rats

June 2022, Chicago, Illinois Poster: Phase 2 pilot trial of RRx-001 as an anti-mucositis agent in head and neck cancer patients treated with chemoradiation (PREVLAR)

May 2022, San Francisco, California Oral Presentation: Inflammation and Immunology: Feature Company Showcase Poster: The ABCs of COVID-19 Related ARDS Treatment Poster: N-VAX, a universal coronavirus vaccine Poster: RRx-001, an NLRP3 inflammasome inhibitor,...

September 2021, Martinsried, Germany Abstract: The direct NLRP3 inhibitor and Phase 3 anticancer agent, RRx-001, ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice

October 2020, Virtual Oral Presentation: Results of a Randomized, Open Label, Multicenter Trial Assessing the Safety, Dose and Schedule of RRx-001 (R001) in Reducing Severe Oral Mucositis (SOM) in Patients Receiving Chemoradiation (CRT) for Oral Cavity/oropharynx...

June 2020, Virtual Poster: Results of a randomized, open-label, multicenter trial to assess the safety, dose, and schedule of RRx-001(001) in reducing incidence, severity and duration of severe oral mucositis (SOM) inpatients receiving concomitant chemoradiation (CRT)...

March 2019, Atlanta, Georgia Abstract: Response to RRx-001 in SCLC is positively correlated with a reduction in CD206(+) HLA-DR(-/low) myeloid-derived suppressor cells

November 2018, New Orleans, Louisiana Abstract: Initial clinical and advanced imaging outcomes from a multi-institutional phase 1 dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases

October 2018, San Antonio, Texas Abstract: Initial clinical and advanced imaging outcomes from a multi-institutional phase I dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases

June 2018, Chicago, Illinois Abstract: QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer

February 2018, San Francisco, California Abstract: Sensitization of neuroendocrine prostate cancer by RRx-001

February 2018, Virtual Abstract: RRx-001 is a phase III aerospace-derived small molecule that immunonormalizes the tumor microenvironment

October 2017, Cancun, Mexico Abstract: Radioprotective effects of RRx-001 on the pathophysiology of the hematopoietic system using a murine radiation model

April 2017, Washington, DC. Abstract: The immunomodulatory anticancer agent RRx-001 induces a vaccine-like interferon response through epigenetic induction of viral mimicry Abstract: Epigenetic and biological effects of 5-azacytidine and RRX-001 on DLD-1 colorectal...

April 2016, New Orleans, Louisiana Abstract: Enhanced uptake and accumulation of temozolomide and irinotecan in orthotopically-implanted gliomas by vascular priming with RRx-001 Abstract: RRx-001 is effective in temozolomide-sensitive and resistant GBM Abstract:...

December 2015, Orlando, Florida Oral Presentation: The hypoxia-selective epigenetic agent, RRx-001, triggers apoptosis and overcomes drug-resistance in multiple myeloma cells

November 2015, Boston, Massachusetts Abstract: RRx-001 combined with anti-PD-L1 antibody increases the complete response rate in a preclinical myeloma model

September 2015, Washington, D.C. Invited Presentation: Restoring efficacy of immunotherapy treatments in oncology with radical oxygen and nitrogen based epigenetic drugs

September 2015, Atlanta, Georgia Abstract: RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing Phase 2 colorectal cancer study, “ROCKET”

May 2015, Toronto, Canada Abstract: RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI in preclinical tumor models

April 2015, Philadelphia, Pennsylvania Abstract: Early results from a phase 2 study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer

March 2015, Paris, France Abstract: Early results: “ROCKET” a phase II study of RRx-001, a novel triple epigenetic inhibitor, resensitization to irinotecan in colorectal cancer

March 2015, Düsseldorf, Germany Abstract: Early results from a phase 2 study of RRx-001, a novel epigenetic modulator, show resensitization to irinotecan in colorectal cancer

March 2015, Seville, Spain Invited Presentation: Early results from a phase 2 study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer

February 2015, San Francisco, California Abstract: RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the Phase 2 “ROCKET” study

Feb 2015, La Jolla, California Abstract: RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the phase 2 “ROCKET” study

October 2014, San Diego, California Abstract: RRx-001 an EXO-based epigenetic anti-cancer agent in phase 2 clinical trials

Apr 2014, San Diego, California Abstract: Molecular imaging of RRx-001-induced oxidative stress in Nrf2-luciferase expressing SCC VII tumors in mice Abstract: RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase Abstract: RRx-001 oxidation...

February 2014, La Jolla, California Abstract: Resensitization to previous chemotherapy with the novel hypomethylating anticancer agent RRx-001

October 2013, Santa Clara, California Oral Presentation: High resolution MS proves that the developmental cancer drug, RRx-001, alkylates the hemoglobin beta chain

May 2013, Kingston, Ontario Abstract: RRx-001, a hypoxia activated, nitric oxide generating cytotoxic agent: Phase 1 study results

April 2013, Washington, D.C. Abstract: Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent

January 2013, La Jolla, California Abstract: Antivascular activity of RRx-001 in SCCVII and U87 tumors Abstract: RRx-001: A novel hypoxia activated nitric oxide generating vascular disrupting agent (VDA) Abstract: Preliminary results from an ongoing phase I trial of...